5:56 PM
 | 
May 15, 2013
 |  BC Extra  |  Clinical News

BMS reports Phase Ib data for Yervoy, nivolumab combo

Bristol-Myers Squibb Co. (NYSE:BMY) reported interim data late Wednesday from 52 evaluable patients showing that concurrent dosing with the pharma's Yervoy ipilimumab plus nivolumab led to an objective response rate (ORR) of 40% in a Phase Ib trial to treat unresectable stage III or stage IV metastatic melanoma. In 17 patients, a concurrent dosing regimen of 3 mg/kg Yervoy...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >